Due to dedicated Clinical Professional and growth of product portfolios, monitoring of Bioequivalence studies from the manufacturers at times in the pharmaceutical business will be critical, IGRS Team shall begin to take up review of Protocol, Country specific RLD information. Monitoring of the study. Submission and Obtaining NOC from DCGI, Reviewing the final Report and submission to Agency.

  IGRS can represent the company and offer our services to ease this burden, whether this is in the form of day-to-day product monitoring including all activity to maintain till the product is dispatched from the desired location and report submission within company portfolio.